Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cisplatin-associated neurotoxicity: can it be prevented?

D S Alberts1, J K Noel

  • 1Department of Medicine, College of Medicine, University of Arizona, Tucson 85724, USA.

Anti-Cancer Drugs
|June 1, 1995
PubMed
Summary

Cisplatin chemotherapy can cause neurotoxicity, particularly peripheral neuropathy. Amifostine shows promise in reducing this side effect, with nerve growth factor also being investigated for prevention.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The impact of junk food marketing regulations on food sales: an ecological study.

Obesity reviews : an official journal of the International Association for the Study of Obesity·2018
Same author

Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data.

Annals of oncology : official journal of the European Society for Medical Oncology·2013
Same author

Promising agents for chemoprevention of skin cancer.

Current oncology (Toronto, Ont.)·2012
Same author

Non-steroidal anti-inflammatory drugs, acetaminophen, and risk of skin cancer in the Nurses' Health Study.

Cancer causes & control : CCC·2012
Same author

Global acetylation and methylation changes predict papillary urothelial neoplasia of low malignant potential recurrence: a quantitative analysis.

International journal of immunopathology and pharmacology·2011
Same author

Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: a Gynecologic Oncology Group study.

Gynecologic oncology·2007

Area of Science:

  • Oncology
  • Neuroscience
  • Pharmacology

Background:

  • Cisplatin is a vital chemotherapy agent, but its use is limited by dose-dependent neurotoxicity, primarily peripheral sensory neuropathy.
  • This neuropathy affects 30-100% of patients, typically after cumulative doses exceeding 300 mg/m², posing a significant clinical challenge.

Purpose of the Study:

  • To evaluate amifostine's efficacy in mitigating cisplatin-induced neurotoxicity and other toxicities.
  • To explore the potential of neurotrophic factors as preventative agents against cisplatin neurotoxicity.

Main Methods:

  • A multicenter phase III trial assessed amifostine pretreatment in ovarian cancer patients receiving cisplatin plus cyclophosphamide.
  • Preclinical studies investigated neurotrophic factors like nerve growth factor (NGF), insulin-like growth factor-I, and neurotrophin-3.

Related Experiment Videos

Main Results:

  • Amifostine pretreatment significantly reduced cisplatin-associated peripheral neuropathy, tinnitus, and nephrotoxicity.
  • Equivalent pathological response rates and median survival were observed between amifostine-treated and control groups.
  • Nerve growth factor demonstrated preventative effects against cisplatin-induced neuropathy in experimental models.

Conclusions:

  • Amifostine is a potential neuroprotective agent that can enhance cisplatin's clinical utility by reducing its toxicity.
  • Neurotrophic factors, particularly NGF, warrant further investigation for their potential to prevent chemotherapy-induced nerve damage.